Patents by Inventor Luc Montagnier

Luc Montagnier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5688637
    Abstract: The invention relates to nucleotidic sequences derived from genomes of the HIV-1 type virus, or from genomes of the HIV-2 type virus, or of the SIV type virus, and their applications, especially as oligo-nucleotidic initiators of implementation of an $i (in vitro) method for the diagnosis of the infection of an individual by a virus of the HIV-1 and/or HIV-2 type.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: November 18, 1997
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Maurice Moncany, Luc Montagnier
  • Patent number: 5677123
    Abstract: Novel mycoplasmas are described which are prominent in patients who are thought to be suffering from AIDS. Devices are also provided for the in vitro detection of mycoplasmas in a biological fluid by means of a reagent which is specific for the mycoplasma group without being specific for particular species within said group. Devices for testing mycoplasma sensitivity to antibiotics are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 14, 1997
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Alain Blanchard, Anne Marie Di Rienzo, Denise Guetard, Veronique Rame
  • Patent number: 5672689
    Abstract: A viral vector comprising at least a portion of the genome of the HIV virus, a gene encoding gp160 glycoprotein of the envelope of the HIV virus, as well as the elements providing for the expression of the glycoprotein in cells, wherein the gp160 is expressed as a non-cleavable protein.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: September 30, 1997
    Assignee: Transgene S.A. and Institute Pasteur
    Inventors: Marie-Paule Kieny, Guy Rautmann, Jean-Pierre Lecocq, Simon Wain Hobson, Marc Girard, Luc Montagnier
  • Patent number: 5610035
    Abstract: A novel human retrovirus which is the aetiological agent of acquired immune deficiency syndrome (AIDS), designated lymphadenopathy-associated virus (LAV), was isolated from the lymph nodes of a patient suffering from generalized persistant lymphadenopathy. LAV displays a tropism for CD4.sup.+ lymphocytes, a Mg.sup.2+ -dependent reverse transcriptase (RT) activity, a density of 1.16-1.17 as determined by sucrose gradient centrifugation, a particle diameter of 139 nm, and a p25 antigen that is immunologically distinct from the HTLV-I/II p24 protein. Radioimmunoprecipitation analysis (RIPA) of .sup.35 S-cysteine-labeled viral or cellular lysates employing patient antisera resulted in the identification of a viral antigen having a molecular weight of 110 kDa. Endoglycosidase treatment of this antigen produces a protein with a molecular weight of 90 kDa. Methods are disclosed for the preparation of hybridomas producing LAV gp110-specific monoclonal antibodies (Mabs).
    Type: Grant
    Filed: September 27, 1994
    Date of Patent: March 11, 1997
    Assignee: Institut Pasteur Centre National de la Recherche Scientific
    Inventors: Luc Montagnier, Bernard Krust, Solange Chamaret, Francois Clavel, Jean-Claude Chermann, Francoise Barre-Sinoussi
  • Patent number: 5597896
    Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type 2 (HIV-2), samples of which have been deposited at CNCM and having Accession Numbers I-502 and I-532. The invention also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp36 and gp130-140 envelope glycoproteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. The invention further relates to polyclonal and monoclonal antibodies specific for the antigens of HIV-2, particularly antibodies specific for gp130-140 envelope glycoprotein. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp36 or gp130-140.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: January 28, 1997
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 5580739
    Abstract: A novel lentivirus, designated the human immunodeficiency virus type 2 (HIV-2.sub.ROD), was isolated from West African patients with acquired immune deficiency syndrome (AIDS). A recombinant lambda phage library was constructed from HIV-2.sub.ROD -infected CEM genomic DNA. Overlapping molecular clones were obtained and the nucleotide sequence of the complete 9.5-kilobase (kb) HIV-2.sub.ROD genome ascertained. The genetic organization of HIV-2 is analogous to that of other retroviruses and consists of the 5'LTR-gag-pol-central region-env-nef-3'LTR. The central region also encodes for the regulatory proteins Tat and Rev, as well as the ancillary proteins Vif, Vpr, and Vpx. The proteins encoded by this proviral clone will provide novel immunologic, biochemic, and diagnostic reagents useful for the detection of HIV-2.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: December 3, 1996
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Geutard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5578715
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: September 4, 1991
    Date of Patent: November 26, 1996
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5550052
    Abstract: The invention relates to new purified antigens of the LAV virus. They have molecular weights of about 135,000 and 150,000 daltons. They are useful for the detection of LAV antibodies in human sera. They are produced by hybrid cell-lines resulting from the fusion of T4 lymphocytes and cells of the MOLT-4 cell line.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: August 27, 1996
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Luc Montagnier, Fran.cedilla.oise Rey, Bernard Krust, Fran.cedilla.ois Clavel
  • Patent number: 5545726
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are-capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: October 7, 1993
    Date of Patent: August 13, 1996
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 5545520
    Abstract: Nucleic acid fragments derived from the HHV6 virus genome and their use in the diagnosis of infections involving this virus.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: August 13, 1996
    Assignees: Institute Pasteur, University Paris - VI
    Inventors: Helene Collandre, Luc Montagnier, Henri Agut, Jean-Marie Bechet
  • Patent number: 5514542
    Abstract: Cell lines which lack human class II histocompatibility antigens are disclosed. The cell lines may be utilized within a method for propagating microorganisms, such as viruses, for determining the presence and/or amount of antibody to a microorganism in a biological fluid, and within a method for producing antibodies to a selected microorganism.
    Type: Grant
    Filed: March 20, 1995
    Date of Patent: May 7, 1996
    Assignees: Genetic Systems Corporation, Institut Pasteur
    Inventors: Robert C. Nowinski, Luc Montagnier, David Klatzmann
  • Patent number: 5470702
    Abstract: Character of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced in HIV-2 infected cells along with three other glycoproteins that were recently reported: the extracellular glycoprotein (gp125), the envelope glycoprotein precursor (gp140), and the transient dimeric form of gp140 (gp300). The gp125 and gp80 were detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 were associated with HIV-2 virions. As the other glycoproteins, gp80 was recognized by all HIV-2 positive sera. A murine polyclonal antibody raised against the purified gp300 recognized all four glycoproteins.
    Type: Grant
    Filed: January 13, 1993
    Date of Patent: November 28, 1995
    Assignee: Institut Pasteur
    Inventors: Ara G. Hovanessian, Marie-Anne Rey, Anne G. Laurent, Bernard Krust, Luc Montagnier
  • Patent number: 5407811
    Abstract: This invention is directed to an isolated antibody specific for gp110 glycoprotein of a human immunodeficiency virus type 1 (HIV-1), and a hybridoma which produces such an antibody. HIV-1 is the causative agent of Acquired Immunodeficiency Syndrome (AIDS).
    Type: Grant
    Filed: September 24, 1992
    Date of Patent: April 18, 1995
    Assignee: Institut Pasteur and Centre National de la Recherche Scientific
    Inventors: Luc Montagnier, Bernard Krust, Solange Chamaret, Francois Clavel, Jean-Claude Chermann, Francoise Barre-Sinoussi
  • Patent number: 5374519
    Abstract: Protein compositions containing the p18 and p25 proteins of the lymphadenopathy virus are used for detecting antibodies in blood serum as indicative of infection by such virus. The proteins can be used in various conventional ways to perform immunoassays for the detection of the antibodies.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: December 20, 1994
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Brun, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
  • Patent number: 5364933
    Abstract: The invention relates to a new variety of retroviruses designated Human Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.
    Type: Grant
    Filed: August 14, 1992
    Date of Patent: November 15, 1994
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 5358937
    Abstract: The glycosylphospholipid nucleoside derivatives of the invention are based on the formula: ##STR1## wherein: R.sub.1 is a nucleoside derivative selected from the group consisting of 3'-azidothymidine (AZT); 2', 3'-dideoxythymidine (ddT); and 2'-deoxy-5-fluorouridine (dFU);R.sub.2 is a hexose or pentose sugar, with the exception of glucose when x is 1;A is a hydrogen atom or an alkyl or alkoxy chain containing from 5 to 20 carbon atoms, said alkyl or alkoxy chain having at its extremity a group selected from the group consisting of a hydrogen atom and an NR'R" group, wherein R' and R" represent hydrogen or an alkyl group of 1 to 4 carbon atoms;x is a number from 1 to 12;y is a number from 1 to 4; andz is 0 or 1; and further wherein:attachment of said hexose sugar is at position 1 or position 6 of said hexose sugar, and attachment of said pentose sugar is at position 1 or position 5 of said pentose sugar.
    Type: Grant
    Filed: September 21, 1992
    Date of Patent: October 25, 1994
    Assignee: Institut Pasteur
    Inventors: Tam Huynh Dinh, Catherine Gouyette, Jean Igolen, Robert Fauve, Luc Montagnier, Yvette Henin, Olivier Schwartz
  • Patent number: 5312902
    Abstract: Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing.
    Type: Grant
    Filed: December 6, 1991
    Date of Patent: May 17, 1994
    Assignees: Institut Pasteur, C.N.R.S.
    Inventors: Luc Montagnier, Ara Hovanessian, Anne Laurent, Bernard Krust, Marie-Anne Rey
  • Patent number: 5310651
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: September 9, 1991
    Date of Patent: May 10, 1994
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel
  • Patent number: 5306614
    Abstract: A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a portion of the genome of HIV-2. In one embodiment, the DNA probes are capable of hybridizing to the entire genome of HIV-2. These reagents also include polypeptides encoded by some of these DNA sequences.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: April 26, 1994
    Assignee: Institut Pasteur
    Inventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
  • Patent number: 5268265
    Abstract: The invention relates to a new variety of retroviruses designated Immunodeficiency Virus Type II, HIV-II, samples of which have been deposited at CNCM as I-502 and I-532. It also concerns purified forms of the antigens which can be obtained from this virus, in particular from the gp 36 and gp 130-140 proteins. These various antigens are useful in medical diagnosis and kits, in particular by being placed in contact with serum of the patient to be diagnosed. Lastly, the invention relates to immunizing compositions, in particular containing at least one of glycoproteins gp 36 and gp 130-140.
    Type: Grant
    Filed: May 17, 1991
    Date of Patent: December 7, 1993
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Denise Guetard, Francoise Brun-Vezinet, Francois Clavel